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Abstract
Background: Publication and outcome reporting bias is often caused by researchers selectively choosing which
scientific results and outcomes to publish. This behaviour is ethically significant as it distorts the literature used for
future scientific or clinical decision-making. This study investigates the practicalities of using ethics applications
submitted to a UK National Health Service (NHS) research ethics committee to monitor both types of reporting bias.
Methods: As part of an internal audit we accessed research ethics database records for studies submitting an end
of study declaration to the Hampshire A research ethics committee (formerly Southampton A) between 1st January
2010 and 31st December 2011. A literature search was used to establish the publication status of studies. Primary
and secondary outcomes stated in application forms were compared with outcomes reported in publications.
Results: Out of 116 studies the literature search identified 57 publications for 37 studies giving a publication rate of
32 %. Original Research Ethics Committee (REC) applications could be obtained for 28 of the published studies.
Outcome inconsistencies were found in 16 (57 %) of the published studies.
Conclusions: This study showed that the problem of publication and outcome reporting bias is still significant in
the UK. The method described here demonstrates that UK NHS research ethics committees are in a good position
to detect such bias due to their unique access to original research protocols. Data gathered in this way could be
used by the Health Research Authority to encourage higher levels of transparency in UK research.
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Background
Reporting bias occurs when the decision of how to publish
a study is influenced by the direction of its results [1]. It is a
well-recognized issue [2] that has recently come to the fore-
front of the public agenda in the UK due to the activities of
the international “AllTrials” petition [3], and the writings of
populist science authors such as Ben Goldacre [4]. Authori-
tative academic analyses have been conducted through the
long-running work of organizations such as the Cochrane
Collaboration and British Medical Journal (among others)
who continue to generate significant public and media
pressure [5].
In December 2011 the Health Research Authority (HRA)
was established in the UK to protect and promote “the
interests of patients and the public in health research” [6].
As part of this remit the HRA was challenged to formulate
proposals to improve transparency in health research [7].
Since the HRA incorporates the National Research Ethics
Service (NRES), whose research ethics committees (RECs)
review and provide ethical opinions on all research using
NHS patients, it seemed logical that the HRA plays a
greater role in monitoring publication outcomes. In re-
cognition of this the HRA business plan for 2013–2014
contains the stated aim of “working with all the relevant
partners to help create an environment where clinical trials
are registered and research results get published” [8].
To investigate the logistics and effectiveness of NHS
research ethics committees monitoring reporting bias we
have determined the publication status of all projects
submitting an end of study declaration to a single re-
search ethics committee over a defined timeframe. We
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have also looked for discrepancies between outcomes
stated in the original ethics application and those re-
ported in the final academic papers.
Methods
Cohort of studies
As part of an internal audit we accessed Integrated Re-
search Application System (IRAS) records of research
projects that submitted an end of study notification to
the South Central, Hampshire A research ethics commit-
tee (formally Southampton A) between 1st January 2010
and 31st December 2011. Studies were stratified from
definitions in the REC forms (see Table 1).
Literature search
Publications were located through a literature search in
three bibliographic databases: Web Of Science, PubMed
and Google Scholar. Search queries used the chief investi-
gator’s last name and keywords from the study title. The
literature search began in October 2013 and additional
new publications monitored until August 2014. A pub-
lication was defined as a peer-reviewed paper published in
an academic journal. Further analysis was carried out on
clinical trials and Clinical Trial of an Investigational
Medicinal Product (CTIMPs) to see if they had been regis-
tered (and had initial results published) on ClinicalTrials.-
gov, the European Clinical Trials Register, or isrctn.org.
These searches used the sponsor’s protocol number, the
European Clinical Trials Database (EudraCT) number, the
International Standard Randomised Controlled Trial
number (ISRCTN) and/or keywords from the study title.
Researchers were not contacted directly so as to deter-
mine the level of information that could be gained from
the publicly available databases alone.
Outcome reporting bias
Outcome reporting was examined by comparing primary
and secondary outcomes originally stated in the REC
Table 1 Characteristics of studies and publication status
Publication status of all studies (n = 116) Reporting outcomes of published studies (n = 28)
Published
37 (32 %)
Unpublished
79 (68 %)
Total 116 Studies with discrepancies
16 (57 %)
Studies consistent with
IRAS form 12 (43 %)
Total 28
Study type
Clinical trial 10 (27 %) 27 (73 %) 37 (32 %) 3 (75 %) 1 (25 %) 4 (14 %)
Clinical Investigation 2 (25 %) 6 (75 %) 8 (7 %) 1 (50 %) 1 (50 %) 2 (7 %)
Questionnaire/mixed methodology 13 (57 %) 10 (43 %) 23 (20 %) 8 (62 %) 5 (38 %) 13 (46 %)
Qualitative study 3 (33 %) 6 (67 %) 9 (8 %) 2 (67 %) 1 (33 %) 3 (11 %)
Tissue or data 4 (27 %) 11 (73 %) 15 (13 %) 1 (25 %) 3 (75 %) 4 (14 %)
Other 1 (13 %) 7 (87 %) 8 (7 %) 1 (100 %) 0 (0 %) 1 (4 %)
Unknown study type 4 (25 %) 12 (75 %) 16 (14 %) 0 (0 %) 1 (100 %) 1 (4 %)
Type of sponsor
NHS or HPSS 16 (35 %) 30 (65 %) 46 (40 %) 7 (50 %) 7 (50 %) 14 (50 %)
Academic 13 (38 %) 21 (62 %) 34 (29 %) 7 (58 %) 5 (42 %) 12 (43 %)
Industry 3 (12 %) 21 (88 %) 24 (21 %) 2 (100 %) 0 (0 %) 2 (7 %)
Unknown sponsor 5 (42 %) 7 (58 %) 12 (10 %) N/A N/A
Number of centres
Single centre 11 (70 %) 26 (30 %) 37 (32 %) 7 (63 %) 4 (36 %) 11 (39 %)
Multi-centre 21 (33 %) 42 (67 %) 63 (54 %) 9 (53 %) 8 (47 %) 17 (61 %)
Unknown 5 (31 %) 11 (69 %) 16 (14 %) N/A N/A
Sample size
<100 14 (29 %) 34 (71 %) 48 (41 %) 7 (50 %) 7 (50 %) 14 (50 %)
≥100 14 (30 %) 33 (70 %) 47 (41 %) 9 (63 %) 5 (36 %) 14 (50 %)
Unknown sample size 9 (43 %) 12 (57 %) 21 (18 %) N/A N/A
Number of papers
1 N/A N/A 11 (58 %) 8 (42 %) 19 (68 %)
>1 N/A N/A 5 (56 %) 4 (44 %) 9 (32 %)
Percentages may not add up to 100 due to rounding. Stratification taken from the REC application form with “unknown” referring to either a missing form or data
missing from the application
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application with those reported in the final publications.
Discrepancies were divided into three categories: 1) a miss-
ing outcome not reported in the final publication, 2) change
of an outcome from primary to secondary (or vice versa),
3) addition of an outcome in the final publication.
Data analysis
Data was analysed using descriptive statistics and odds
ratios calculated using MedCalc 13 [9].
Ethics and data-access
Ethical approval was not required from a statutory com-
mittee for this work. Raw data is not available due to the
researchers unique access to the research ethics database
as members of a REC.
Results
Included studies
A total of 116 studies were included in this study. As the
inclusion criteria were based upon end of study notifica-
tions, original ethics applications were dated between
2003 and 2011. Characteristics of the included studies
are shown in Table 1. The type of study design was un-
clear for 16 studies, the type of sponsor unknown for 12
studies, the number of centres unknown for 16 studies
and the sample size unknown for 21 studies due to lack
of information in the REC application. Thirty studies in
the cohort contributed towards an educational degree.
Publication outcomes
The literature search identified 57 publications for 37 stud-
ies giving an overall publication rate of 32 %. Twenty-one
studies had been presented as a conference abstract, 11 of
which also had a journal publication. A conference abstract
alone was not considered a publication in line with previous
studies due to the lack of information inherent in this type
of report [10]. Twenty-five studies had more than one pub-
lication (range 1–6). Industry sponsored studies were sig-
nificantly less likely to be published than studies sponsored
by academic institutions, the NHS or Health and Personal
Social Services (HPSS) sponsored studies (OR = 0⋅25,
p = 0 · 04, CI 0⋅07-0⋅92). Attempts to stratify the data in
other ways produced no significant results using simple
odds-ratio calculations. Of the 37 studies that published at
least one paper, the mean time for publication (from date
of ethics submission) was 3⋅9 years with the highest num-
ber of studies (11) publishing between 3 and 4 years
(Fig. 1a). Of 37 clinical trials in this cohort, 26 were regis-
tered on the ClinicalTrials.gov website with five (19 %)
having posted summary results. Twenty-two out of 27
CTIMPs were registered through EudraCT with only one
of the missing five on ClinicalTrials.gov. Only 5 of the 37
clinical trials were registered on the ISRCTN registry, four
of which were on ISRCTN only and one on all three data-
bases. This gave 7 out of 37 clinical trials (with 4
CTIMPs) not registered on any of the three main trial
registration databases, although these trials had com-
menced prior to the requirement for registration.
Consistency of outcomes
Full REC applications were available for twenty-eight
studies for analysis of outcome-reporting bias (Table 1).
A total of 141 outcomes were identified across the 28
studies from the original REC applications. These in-
cluded 50 primary outcomes and 91 secondary out-
comes. The median number of primary outcomes was 1
(range 1–6) and the median number of secondary out-
comes was 3 (range 1–11). Four studies did not have
any secondary outcomes stated whilst twelve studies had
more than one primary outcome. Out of the 141
planned outcomes 32 (23 %) were missing in the final
publications, including 6 unreported primary outcomes.
Twelve studies (43 %) were entirely consistent with their
original REC form whilst 16 (57 %) studies had discrep-
ancies (Fig. 1b). Fourteen studies had missing outcomes
including 3 clinical trials, 8 questionnaire/mixed me-
thodology studies and 2 qualitative studies. One study
categorised as “other” reported a statistically significant
secondary outcome as a primary outcome (Fig. 1c). One
tissue study had a new subgroup analysis in the publica-
tion that was not mentioned in the REC form.
Amongst the studies with unreported outcomes, six stu-
dies had at least one unreported primary outcome and
thirteen studies had at least one unreported secondary out-
come. The median proportion of unreported outcomes per
study was 38 % (CI 25 %-75 %). There was a weak correl-
ation between the number of papers a study produced and
the percentage of reported outcomes (p = 0·94). There was
no correlation between the number of outcomes and the
percentage of reported outcomes (p = 0·62).
Discussion
If the reporting of research is a fundamentally ethical issue
[11–13] it seems well within the remit of research ethics
committees to encourage researchers to commit to pub-
lishing results as a condition of ethical approval as well as
monitoring subsequent publications [14]. Although it is
appreciated that research can be reported in a number of
different ways, this study chose to only look at the peer-
reviewed scientific literature as this is the main source of
information for the expert community who are best
placed to utilise research outcomes. The publication rate
of 32 % is consistent with previous studies conducted by
research ethics committees that have found publication
rates in the range of 20 %-76 % [15–18]. However, unlike
many countries where such studies can only really provide
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snapshots from individual hospitals or regions, extending
the method described here across the whole HRA ethics
system could potentially capture national data and per-
haps provide a continuous monitoring service for the UK.
The main weakness of this study was the short time avail-
able to researchers for data analysis and publication (a max-
imum of three years since end of study notification),
especially as the literature seems to show that especially
clinical drug trials publish on average between 4 and 8 years
after a study [14]. However, this widely quoted timeframe is
ambiguous because it is unclear whether it is measured
from when the studies started or when they were com-
pleted. If the original date of submission to the Hampshire
A research ethics committee is used, the studies analysed in
this paper had between 2 and 10 years to publish at least
some sort of peer reviewed result or commentary. It may
be hoped that the percentage of projects publishing might
improve as time goes on, but the data did show a mean
time of 3⋅9 years between initial ethics application and
publication for the studies that did publish (Fig. 1a),
suggesting that the timeframe used here is not unreason-
able. Other weaknesses included limiting this study to a
single research ethics committee and not contacting re-
searchers to determine reasons for non-publication. How-
ever, the purpose of this study was to determine a simple
method that could reasonably be applied by individual
RECs without extensive research funding.
Attempts to stratify the studies did not give significant
p values for most study characteristics based upon a
simple odds ratio calculation [19]. The only significant
difference was with studies sponsored by industry that
only showed a 12 % publication rate, compared to
around 30 % for other types of sponsors. The reason for
this cannot be determined here, but is consistent with
the perception that industry suppresses results [20].
Unreported outcomes were the main reporting dis-
crepancy identified between original REC applications
and final publications. The figure of 57 % overall dis-
crepancy between the originally planned outcomes and
those reported in the final application is consistent with
previous literature where discrepancies in reporting of
primary outcomes were found in 62-66 % of clinical tri-
als [21, 22]. Again conducting this study from within the
HRA system proved particularly powerful as original
REC application forms could be analysed. However,
administrative changes between 2003 and the current
time meant that electronic copies of REC forms were
only available for a small number of studies, whilst some
paper REC forms had already been discarded, so not all
published studies could be included in this analysis. It
was also not clear whether additional information from
all study amendments had been located.
Conclusion
The results described here demonstrate that NHS research
ethics committees are able to effectively monitor publica-
tion and outcome reporting bias. This is significant because
these committees hold complete records of all human
research that is subject to certain legal regulation or con-
ducted within the NHS. This places them in a stronger pos-
ition than individual sponsors or research funders when it
comes to auditing or monitoring reporting bias. However,
such monitoring is not currently part of their remit. At the
moment committees are composed of up to eighteen vol-
unteer members and one REC manager, reviewing approxi-
mately 45 full applications per year. Although this project
included just a subset of studies from one committee, it oc-
cupied a full-time masters student for most of a year. This
would have significant resource implications on RECs and
the HRA if comprehensive monitoring identical to this
study was to be carried out for all studies submitted to all
68 committees currently overseen by the HRA. An alterna-
tive might be to conduct smaller studies such as described
here on a regular basis, not for policing researchers, but ra-
ther to allow the monitoring of various ways to encourage
researchers to publish both their projects as a whole and
the outcomes they had originally committed to measure.
Fig. 1 a Time taken between initial ethics submission and the first publication for the 37 studies that published. b Percentage of published
studies that were consistent with IRAS form (n = 28). c Types of discrepancies identified between initial application and final publication
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